Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia

被引：7

作者：

de Vries, Andrica C. H. ^{[1
]}

Stam, Ronald W. ^{[1
]}

Schneider, Pauline

Niemeyer, Charlotte M. ^{[2
]}

van Wering, Elisabeth R. ^{[3
]}

Haas, Oskar A. ^{[4
]}

Kratz, Christian P. ^{[2
]}

den Boer, Monique L. ^{[1
]}

Pieters, Rob ^{[1
]}

van den Heuvel-Eibrink, Marry M. ^{[1
,3
]}

机构：

[1] Erasmus MC, Sophia Childrens Hosp, Pediat Oncol Hematol, Rotterdam, Netherlands

[2] Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Freiburg, Germany

[3] Dutch Childhood Oncol Grp, The Hague, Netherlands

[4] Childrens Canc Res Inst, Vienna, Austria

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 11期

关键词：

FLT3; JMML; PKC412;

D O I：

10.3324/haematol.11201

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FLT3 gene mutations have been identified as prognostic factors in myeloid malignancies. Furthermore, FLT3 can be activated by wild type overexpression or liganddependent in leukemic cells co-expressing FLT3 ligand (FLT3L). So far no data are available on FLT3/FLT3L expression and activation in JMML. In 51 clinical JMML samples, activating mutations were screened, FLT3 and FLT3L mRNA levels were assessed and the sensitivity of JMML cells to the FLT3 inhibitor PKC412 was tested by MTT assays. No evidence for constitutively activation of FLT3/FLT3L was found in JMML, indicating that FLT3 inhibitors are unlikely to be effective in JMML.

引用

页码：1557 / 1560

页数：4

共 19 条

[1] Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].

Armstrong, SA ;

Kung, AL ;

Mabon, ME ;

Silverman, LB ;

Stam, RW ;

Den Boer, ML ;

Pieters, R ;

Kersey, JH ;

Sallan, SE ;

Fletcher, JA ;

Golub, TR ;

Griffin, JD ;

Korsmeyer, SJ .

CANCER CELL, 2003, 3 (02) :173-183

[2]

BRASEL K, 1995, LEUKEMIA, V9, P1212

[3] RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML) [J].

Flotho, C ;

Valcamonica, S ;

Mach-Pascual, S ;

Schmahl, G ;

Corral, L ;

Ritterbach, J ;

Hasle, H ;

Aricò, M ;

Biondi, A ;

Niemeyer, CM .

LEUKEMIA, 1999, 13 (01) :32-37

[4] Expression of the Evi-1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors [J].

Gerhardt, TM ;

Schmahl, GE ;

Flotho, C ;

Rath, AV ;

Niemeyer, CM .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :882-887

[5] Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia [J].

Gratias, EJ ;

Liu, YL ;

Meleth, S ;

Castleberry, RP ;

Emanuel, PD .

PEDIATRIC BLOOD & CANCER, 2005, 44 (02) :142-146

[6]

Kiyoi H, 1999, BLOOD, V93, P3074

[7] Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis [J].

Kong, ANT ;

Yu, R ;

Chen, C ;

Mandlekar, S ;

Primiano, T .

ARCHIVES OF PHARMACAL RESEARCH, 2000, 23 (01) :1-16

[8] Allogenic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood [J].

Locatelli, F ;

Niemeyer, C ;

Angelucci, E ;

BenderGotze, C ;

Burdach, S ;

Ebell, W ;

Friedrich, W ;

Hasle, H ;

Hermann, J ;

Jacobsen, N ;

Klingebiel, T ;

Kremens, B ;

Mann, G ;

Pession, A ;

Peters, C ;

Schmid, HJ ;

Stary, J ;

Suttorp, M ;

Uderzo, C ;

vantVeerKorthof, ET ;

Vossen, J ;

Zecca, M ;

Zimmermann, M .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :566-573

[9]

NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45

[10]

Niemeyer CM, 1997, BLOOD, V89, P3534

← 1 2 →